Generic drugs
3 articles
Accessible DAAs Shouldn’t Be DOA: Delivering on the Promise of Negotiated Price Reductions for HCV Treatment
The hepatitis C virus remains one of the deadliest infectious diseases, despite the existence of an effective eight-to-twelve week cure. Access to direct acting antivirals must be urgently expanded to save lives. More
The Potential Impact of the Comprehensive and Progressive Agreement for Trans-Pacific Partnership on Thailand’s Hepatitis C Treatment Program
Acceding to trade agreements such as the CPTPP that require increasing intellectual property protection, could compromise Thailand’s hepatitis C program and other national treatment programs reliant on affordable generic medicines. More
TAG and LAT CAB Welcome Indian Patent Office Decision That Could Expand Access to Hepatitis C Treatment
TAG and the LAT CAB celebrate the Indian Patent Office’s decision to NOT grant a patent on the HCV combination treatment glecaprevir/pibrentasvir, aka Mavyret® or Maviret® manufactured by AbbVie. More
